riociguat: Clinical Trials

58 trials of riociguat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 9 terminated, 3 recruiting, 3 unknown. 19 Phase 2, 12 Phase 1, 9 Phase 3, 8 Phase 4, 4 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 219Completed 9, Terminated 7, Unknown 2, Withdrawn 1
Phase 112Completed 12
Phase 39Completed 5, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 48Completed 4, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Not applicable4Completed 4

Follow riociguat: new trials by email Literature Review of riociguat trials Research Report on riociguat

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)
Riociguat, Routine Treatment - Chronic Thromboembolic Pulmonary Hypertension
Phase 3RecruitingSuqiao Yang682025-03-212025-04-30
Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH
Macitentan Tablets, Riociguat, balloon pulmonary angioplasty - CTEPH
Phase 3TerminatedDr Sudarshan Rajagopal72025-01-272026-09-03
Switching of Sildenafil to Riociguat in CTEPH Patients
Riociguat (Adempas) - Chronic Thromboembolic Pulmonary Hypertension
Phase 4RecruitingChinese University of Hong Kong302024-07-252025-05-29
Pulmonary Hypertension: Intensification and Personalisation of Combination Rx
Selexipag, Riociguat, CardioMEMS pulmonary artery pressure monitor - Pulmonary Arterial Hypertension
Phase 4Active not recruitingSheffield Teaching Hospitals NHS Foundation Trust702023-06-142026-08-07
Effect of Riocigaut on Migraine Attack Induction in People With Migraine
Riociguat (BAY 63-2521), Placebo - Migraine Without Aura
Not applicableCompletedDanish Headache Center222023-06-012024-07-12
Bioequivalence Study of Riociguat 2.5 mg Film Coated Tablets and Adempas (Riociguat) 2.5 mg Film Coated Tablets
Riociguat film coated tablets, Adempas Filmtabletten - Pulmonary Arterial Hypertension
Phase 1CompletedHumanis Saglık Anonim Sirketi362023-03-072023-12-28
Effect of Riocigaut on Cerebral Vasodilation and Headache Induction in Healthy Volunteers
Dose Riociguat 2,5 or 5mg, Riociguat, Placebo - Headache
Not applicableCompletedDanish Headache Center152022-10-262024-01-05
Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Riociguat Oral Tablet, Placebo - Pulmonary Vascular Disorder, Primary Pulmonary Hypertension
Phase 2TerminatedHeidelberg University352022-10-242026-01-21
Networked Drug REpurposing for Mechanism-based neuroPrOtection in Acute Ischaemic STROKE
Riociguat, Propylthiouracil, Perphenazine - Ischemic Stroke, Acute
Phase 2UnknownMaastricht University282022-09-052023-10-19
Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH
Riociguat - Primary Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Phase 4TerminatedHeidelberg University302022-04-132026-06-17
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Riociguat (Adempas, BAY63-2521) - Pulmonary Arterial Hypertension
CompletedBayer5002021-07-162025-02-10
Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers
Propylthiouracil, Riociguat, Perphenazine - Drug Drug Interaction, Safety Issues
Phase 1CompletedMaastricht University82021-03-182022-04-04
THERAPY-HYBRID-BPA Trial
Riociguat Oral Tablet - Hypertension, Pulmonary
Phase 2UnknownNational Hospital Organization Okayama Medical Center722020-10-162020-10-23
A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants
Macitentan, Sildenafil, Riociguat - Healthy
Phase 1CompletedActelion472020-01-142025-03-30
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
Treprostinil Injectable Product, Riociguat Pill - Pulmonary Arterial Hypertension
Phase 3RecruitingUniversity of Arizona202019-03-252025-02-20
Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)
Riociguat, Placebo, Pulmonary endarterectomy - Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Phase 2TerminatedInternational CTEPH Association142018-08-172021-06-22
Treatment of Exercise-Induced Pulmonary Vascular Dysfunction After Pulmonary Thromboendarterectomy or Balloon Pulmonary Angioplasty
Adempas - Chronic Thromboembolic Disease (CTED), Exercise Intolerance Post PEA Surgery
Phase 2CompletedUniversity of Colorado, Denver102018-06-132026-02-05
Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics
Riociguat (Adempas), Macitentan (Opsumit) - Healthy Subjects
Phase 1CompletedActelion202018-01-092018-02-08
A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases
Riociguat, Placebo - Sickle Cell Disease
Phase 2CompletedMark Gladwin1302017-04-112023-07-19
Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension
Riociguat, Pulmonary Endarteriectomy, Ballon Pulmonary Angioplasty - Chronic Thromboembolic Pulmonary Hypertension, Sleep Disordered Breathing
Not applicableCompletedMedical University of Vienna502017-02-012023-03-14

Showing 20 of 58. Sign in to see all of them.

Conditions studied

Hypertension, Pulmonary (25)  ·  Pulmonary Arterial Hypertension (12)  ·  Ventricular Dysfunction, Left (3)  ·  Headache (2)  ·  Scleroderma, Systemic (2)  ·  Altitude Sickness (1)  ·  Anemia, Sickle Cell (1)  ·  Coronary Artery Disease (1)  ·  Cystic Fibrosis (1)  ·  Familial Primary Pulmonary Hypertension (1)  ·  Hypertension (1)  ·  Idiopathic Interstitial Pneumonias (1)  ·  Ischemic Stroke (1)  ·  Limb-girdle muscular dystrophy, type 2E (1)  ·  Migraine Disorders (1)

Sponsors

Bayer (34)  ·  Actelion (2)  ·  Danish Headache Center (2)  ·  Heidelberg University (2)  ·  Maastricht University (2)  ·  Medical University of Vienna (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Chinese University of Hong Kong (1)  ·  Dinesh Khanna, MD, MS (1)  ·  Dr Sudarshan Rajagopal (1)  ·  Humanis Saglık Anonim Sirketi (1)  ·  International CTEPH Association (1)  ·  Mark Gladwin (1)  ·  National Hospital Organization Okayama Medical Center (1)  ·  Richard Moon (1)

Countries

Germany (32)  ·  United States (25)  ·  France (16)  ·  United Kingdom (16)  ·  Belgium (14)  ·  Italy (14)  ·  Japan (14)  ·  Austria (13)  ·  Canada (13)  ·  Czechia (12)  ·  Denmark (11)  ·  Switzerland (11)  ·  Turkey (Türkiye) (11)  ·  Spain (9)  ·  Australia (8)

Top investigators

Alexander Rothman, MD / PhD (1)  ·  David Jenkins, MD (1)  ·  Diana Bonderman, MD (1)  ·  Dinesh Khanna, MD (1)  ·  Franz Rischard, DO (1)  ·  Irene Lang, Prof. (1)  ·  Johannes Kastner, MD (1)  ·  Mark Gladwin, MD (1)  ·  Messoud Ashina, MD (1)  ·  Messoud B Ashina, MD, Phd, DMSc (1)  ·  Peter Sottile, MD (1)

Results publications

PMID 27162632, PMID 27263466, PMID 34353714, PMID 23883377, PMID 23883378, PMID 23883383, PMID 26135803, PMID 27067478, PMID 27326239, PMID 27457511, PMID 34848133, PMID 35256218, PMID 19705340, PMID 20530034, PMID 22719060, PMID 22936711, PMID 23775260, PMID 24991733, PMID 25614164, PMID 25657022, PMID 26910470, PMID 27067479, PMID 27106231, PMID 27887774, PMID 27890471, PMID 28011757, PMID 28610669, PMID 28889107, PMID 29282032, PMID 31416769, PMID 31481106, PMID 32754307, PMID 33773120, PMID 34224432, PMID 34363816, PMID 34419414, PMID 34889382, PMID 35926542, PMID 37407055, PMID 38251533, PMID 38460548, PMID 38554715, PMID 39965044, PMID 40371623, PMID 40714010, PMID 41484960, PMID 42023995, PMID 42457022, PMID 42538528

NIH funding

2008 (5), 2014 (4), 2009 (3), 2016 (2), 2019 (2), 2023 (2), 2017 (1)